Skip to main content

Table 4 ANOVA analysis comparing patients with and without recieving durvalumab maintenance therapy regarding LDH, hemoglobin, leukocytes, thrombocytes, GOT, GPT and albumin

From: Longitudinal changes of blood parameters and weight in inoperable stage III NSCLC patients treated with concurrent chemoradiotherapy followed by maintenance treatment with durvalumab

Parameter Baseline Begin Durvalumab 3 months FU 6 months FU 9 months FU 12 months FU
p-value p-value p-value p-value p-value p-value
LDH 0.784 0.440 0.349 0.589 0.965 0.537
Hemoglobin 0.774 0.530 0.196 0.222 0.015 0.115
Leukocytes 0.528 0.413 0.882 0.778 0.336 0.762
Thrombocytes 0.294 0.835 0.749 0.929 0.757 0.122
GOT 0.724 0.053 0.421 0.883 0.949 0.827
GPT 0.291 0.096 0.060 0.048 0.199 0.284
Albumin 0.538 0.116 0.967 0.304 0.164 0.195